Skip to content

Home
About Me
News and updates
Knowledge vault
Contact
Newsletter

German Market Access – Simplified

Everything you need to know in one place, explained in simple terms

RWE

« Back to Glossary Index

real-world evidence

Related

« Back to Glossary Index

Previous

Next

Hi, I'm Anja. Thanks for visiting German Market Access Simplified. I hope you enjoy the website. Click around and let me know how I can help! I look forward to connecting with you.

AMNOG law
Costs
Directives
DMPs
Early benefit assessments
German traditions
Hospital treatments
Innovation funds
IQWiG
Method assessments
News and updates
Orphan drugs
Previous G-BA decisions
Pricing
Regulatory
Reimbursement
Uncategorized

Recently published

G-BA decisions from 7 November 2024
G-BA decisions from 22 November 2024
G-BA decisions from 17 October 2024
G-BA decisions from 2 Oct 2024
G-BA decisions from 19 September 2024
G-BA decisions from 15 Aug 2024
G-BA decisions from 1 Aug 2024
G-BA decisions from 18 July 2024
G-BA decisions from 4 July 2024
Determining the Reimbursed Price for Pharmaceuticals in Germany: An Overview

Recent Comments

EU regulation for in-vitro diagnostics — German Market Access – Simplified on Can the expected medical device shortages in Germany be stopped?
Anja Pownell on Lung cancer drug taken off German market because of no additional benefit rating
Grace on Lung cancer drug taken off German market because of no additional benefit rating
Another cancer drug by Janssen unlikely to be available in Germany on Lung cancer drug taken off German market because of no additional benefit rating
Anja Pownell on Federal Cabinet has agreed new law to stabilise SHI finances

Share this page

Search

Privacy policy and disclaimer

Powered by WordPress

All rights reserved © German Market Access – Simplified All Colors Theme by Seos Themes

Want my free guide about German HTA?

Find out more!
X